Followers | 177 |
Posts | 24553 |
Boards Moderated | 13 |
Alias Born | 04/03/2002 |
Wednesday, June 09, 2021 1:02:05 PM
Outstanding Shares
11,232,921
https://www.otcmarkets.com/stock/ARDS/profile ;
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company is utilizing its proprietary PEX™ and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.
The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.
Recent ARDS News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:02:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 11:05:19 AM
- Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024 • GlobeNewswire Inc. • 12/15/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:00:31 PM
- Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/03/2023 08:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2023 10:15:10 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/14/2023 01:47:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/25/2023 08:05:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/04/2023 08:05:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/04/2023 08:05:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/03/2023 08:15:38 PM
- Aridis Pharmaceuticals Announces $2 Million Offering • GlobeNewswire Inc. • 08/02/2023 12:17:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2023 04:15:14 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/21/2023 10:49:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:18:38 PM
- Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301 • GlobeNewswire Inc. • 07/17/2023 08:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/17/2023 07:01:05 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/17/2023 11:36:32 AM
- Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation • GlobeNewswire Inc. • 07/12/2023 12:00:00 PM
- Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) • GlobeNewswire Inc. • 06/20/2023 12:00:00 PM
- Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 06/08/2023 08:05:00 PM
- Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design • GlobeNewswire Inc. • 05/31/2023 12:00:00 PM
- Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q • GlobeNewswire Inc. • 05/25/2023 08:05:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM